查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1933856

磁振造影引导聚焦超音波治疗系统市场：按机制、产品、最终用户和适应症划分－全球预测，2026-2032年

Magnetic Resonance Guided Focused Ultrasound Therapy System Market by Mechanism, Offering, End User, Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年磁振导航导引超音波治疗系统市值为5.9728亿美元，预计2026年将成长至6.8424亿美元，复合年增长率为13.88%，到2032年将达到14.8372亿美元。

关键市场统计数据
基准年 2025 5.9728亿美元
预计年份：2026年 6.8424亿美元
预测年份 2032 14.8372亿美元
复合年增长率 (%) 13.88%

本文简要概述了磁振造影（MRI）引导超音波（MRgFUS）作为一种整合型治疗平台，如何影响临床路径、机构准备和转化研究。

磁振造影引导超音波（MRgFUS）正从一种小众研究手段转变为多个临床专科微创治疗策略的基础。本文将该技术描述为高解析度成像、精准能量传递和不断发展的临床通讯协定的完美结合，这些技术共同实现了标靶组织消融、神经调控以及新型药物递送技术的进步。接下来的说明将MRgFUS定位为一个整合的平台，它不仅是一种设备类别，更连结了诊断影像、手术流程和转化研究。

临床检验、模组化架构和跨学科合作如何重塑核磁共振导引聚焦超音波的推广路径和商业性竞争格局

磁振造影引导聚焦超音波（MRgFUS）领域正经历着变革性的转变，这主要得益于临床检验、模组化技术架构以及不断拓展的治疗目标。临床证据正从个案研究扩展到多中心研究，这些研究检验MRgFUS在神经肿瘤、运动障碍和肿瘤适应症的疗效和安全性。因此，医疗机构正在重新思考MRgFUS的部署方式。他们不仅将MRgFUS作为独立的治疗手段，更将其视为一种可以整合到手术室、介入放射学工作流程和研究中心的先进技术。

评估供应链、采购和商业模式调整对2025年美国对核磁共振导引聚焦超音波治疗实施的累积关税的影响。

2025年关税的累积影响为磁共振引导聚焦超音波（MRgFUS）价值链上的相关人员带来了复杂的营运和策略考量。进口组件、成像子系统和精密製造投入的关税将推高系统製造商的成本，并可能对整个分销管道产生连锁反应。这些成本压力迫使製造商重新评估其供应商基础，加快关键组件的在地采购，并重新谈判供应合同，以维持毛利率并避免医疗机构价格突然波动。

深度細項分析揭示了终端使用者专业领域、治疗机制、产品供应和临床适应症如何影响产品采纳、证据需求和商业化策略。

一个稳健的细分框架揭示了最终用户、作用机制、产品供应和适应症对临床应用、产品开发和商业化的细微影响。从最终用户的观点来看，门诊手术中心细分为癌症中心和诊断影像中心等次专科，优先考虑手术量、患者体验和可预测的手术时间。同时，公立和私立医院都致力于整合复杂的诊疗路径并获得机构认证。研究机构分为学术研究机构和药物研发部门，强调转化研究和药物研发合作。此外，神经外科和肿瘤中心等专科诊所专注于疑难病例和多学科协作。

美洲、欧洲、中东和非洲以及亚太地区的区域监管差异、基础设施优先事项和临床合作模式都会影响科技的采纳和商业化策略。

区域趋势在塑造临床应用、监管策略和商业性执行方面发挥着至关重要的作用。在美洲，报销框架、不断演变的临床指南以及介入放射学和神经外科中心的成熟度正在限制机构投资者的投资意愿。三级转诊中心和综合癌症计画的病患需求与能够为特定适应症提供低成本、高效率治疗的门诊手术中心的需求趋于一致。这些因素正在影响供应商的市场推广重点，并促使他们调整服务协议以适应医院的采购週期。

生态系统分析着重于製造商、创新新参与企业和策略联盟如何推动技术差异化、服务模式和临床合作。

主要企业的发展趋势正日益受到医疗设备製造商、影像合作伙伴、临床研究机构和专业服务供应商组成的生态系统的影响，而非单一市场领导的影响。成熟的医疗设备製造商拥有监管经验、全球服务网路和资金管道等优势，使其能够扩展复杂的设备并提供一体化的维护合约。同时，创新Start-Ups公司正透过专注的临床项目、演算法治疗方案以及诸如增强血脑障壁调节和微气泡辅助递送等新型机制，推动市场差异化。

为产业领导者提供实用策略指南，以加速磁振造影引导聚焦超音波（MRgFUS）技术的应用，建立临床伙伴关係，并降低商业化和供应链执行风险。

产业领导者应采取多管齐下的策略，整合技术开发、临床证据产生和商业性柔软性，以加速技术应用并降低投资风险。首先，应优先考虑模组化产品设计和改造方案，以降低医疗系统的初始资金投入门槛，并加快在学术机构和高运作社区医疗中心进行概念验证部署。此外，还应辅以有针对性的培训和认证项目，以减少临床结果的差异性并培养内部倡导者。

本执行摘要清楚地描述了一种混合方法研究方法，该方法结合了主要临床访谈、次要证据综合和专家检验，以确保得出可靠、可操作的研究结果。

本执行摘要的调查方法融合了初步定性研究、严谨的二手研究以及反覆的专家检验，以确保其可靠性和实用性。初步数据是透过对神经外科、介入放射科和肿瘤科的临床负责人，以及负责影像实验室管理和资本规划流程的采购和技术运营相关人员进行结构化访谈收集的。这些访谈直接揭示了临床工作流程、训练需求和采购决策标准。

一份综合分析和未来展望报告，重点阐述了製造商、临床医生和支付方为实现磁振造影引导聚焦超音波（MRgFUS）的持续普及必须采取的合作行动。

总之，核磁共振导引聚焦超音波治疗正处于关键的转折点，临床创新、商业化策略和营运执行的交汇点将决定其应用的速度和规模。不断增长的临床证据、模组化技术的趋势以及与製药和影像合作伙伴的策略合作，正在重新定义非侵入性治疗和标靶药物递送的可能性。医疗机构能否成功应用该技术，取决于相关人员能否将该技术与临床路径整合，同时确保一致的培训、服务的可靠性和疗效评估。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 磁振造影引导聚焦超音波治疗系统市场（依机制划分）

  • 血脑障壁开放
  • 药物输送
    • 封装药物载体
    • 微气泡导递送
    • 精准投放
  • 组织溶解疗法
  • 神经调控
    • 深部脑部刺激
    • 非侵入性神经调控
  • 热凝固疗法

9. 磁振造影导引聚焦超音波治疗系统市场（依产品/服务分类）

  • 配件和零件
    • 配件
    • 消耗品
    • 替换零件
  • 服务
    • 咨询和培训
    • 安装和维护
  • 系统
    • 磁振导航系统
    • 超音波引导系统

第十章 磁振造影导引超音波治疗系统市场（依最终使用者划分）

  • 门诊手术中心
    • 癌症中心
    • 诊断影像中心
  • 医院
    • 私立医院
    • 公立医院
  • 研究所
    • 学术研究机构
    • 药物研究与开发研究所
  • 专科诊所
    • 神经外科中心
    • 肿瘤中心

第十一章 磁振造影导引聚焦超音波治疗系统市场（依适应症划分）

  • 骨转移
  • 乳癌
  • 自发性震颤
  • 肝臟肿瘤
  • 神经系统疾病
    • 脑肿瘤
    • 运动障碍
    • 神经病变疼痛
    • 帕金森氏症
  • 胰臟肿瘤
  • 摄护腺癌
  • 子宫肌瘤

12. 磁振造影引导聚焦超音波治疗系统市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 磁振造影导引聚焦超音波治疗系统市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国磁振造影引导聚焦超音波治疗系统市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国磁振造影引导聚焦超音波治疗系统市场

第十六章 中国磁振造影导引聚焦超音波治疗系统市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alpinion Medical Systems Co., Ltd.
  • Canon Medical Systems Corporation
  • Chongqing Haifu Technology Co., Ltd.
  • EDAP TMS SA
  • EDAP-affiliated product lines
  • EpiSonica
  • EyeTechCare
  • FUJIFILM Holdings
  • FUS Instruments
  • General Electric Company
  • Hitachi, Ltd.
  • Insightec Ltd.
  • Koninklijke Philips NV
  • Medtronic plc
  • Mianyang Sonic Electronic
  • Mirabilis Medical
  • Profound Medical
  • Shanghai A&S Science & Technology
  • Shenzhen Wikkon Medical Technology
  • Siemens Healthineers AG
  • SonaCare Medical
  • SuperSonic Imagine
  • Theraclion SA
Product Code: MRR-C36616F69986

The Magnetic Resonance Guided Focused Ultrasound Therapy System Market was valued at USD 597.28 million in 2025 and is projected to grow to USD 684.24 million in 2026, with a CAGR of 13.88%, reaching USD 1,483.72 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 597.28 million
Estimated Year [2026] USD 684.24 million
Forecast Year [2032] USD 1,483.72 million
CAGR (%) 13.88%

A concise orientation to MR-guided focused ultrasound as a convergent therapeutic platform shaping clinical pathways, institutional readiness, and translational research

Magnetic resonance guided focused ultrasound (MRgFUS) is transitioning from a niche investigational modality to a cornerstone of minimally invasive therapeutic strategies across multiple clinical specialties. This introduction frames the technology as a convergence of high-resolution imaging, precise energy delivery, and evolving clinical protocols that together enable targeted tissue ablation, neuromodulation, and facilitation of novel drug delivery techniques. The narrative that follows positions MRgFUS not just as a device category but as an integrative platform that interfaces with imaging, surgical workflows, and translational research.

Over recent years, momentum has been driven by iterative improvements in MR imaging sequences, enhanced patient workflow integration, and growing clinical evidence across indications ranging from benign gynecologic disease to neurologic conditions. Stakeholders across institutional, research, and commercial settings are assessing how MRgFUS can reduce procedural morbidity, shorten recovery times, and enable previously infeasible therapeutic pathways. As adoption accelerates, strategic questions about site of care readiness, training requirements, reimbursement pathways, and supply chain resilience become central to implementation planning.

This introduction sets the context for deeper analysis of market dynamics, technology differentiation, regulatory headwinds, and competitive positioning. It underscores the need for cross-functional alignment among clinicians, imaging teams, hospital administrators, and commercial partners to convert clinical promise into sustainable clinical programs and reproducible patient outcomes.

How clinical validation, modular architectures, and cross-disciplinary partnerships are reshaping adoption pathways and commercial competition in MR-guided focused ultrasound

The MRgFUS landscape is experiencing transformative shifts driven by clinical validation, modular technology architectures, and expanding therapeutic ambitions. Clinical evidence is broadening from isolated case series to multicenter experiences that validate efficacy and safety across neuro-oncology, movement disorders, and oncologic indications. As a result, institutional adoption is being reimagined: centers are evaluating MRgFUS not only for discrete procedures but as a capability that can be integrated into surgical suites, interventional radiology workflows, and research cores.

Technological evolution is also reshaping the competitive environment. Systems are migrating toward more modular offerings that enable retrofit integration and hybrid imaging guidance, while software advances in treatment planning and real-time monitoring increase procedural confidence. Concurrently, translational initiatives such as blood-brain barrier modulation and microbubble-mediated delivery are expanding the potential therapeutic payloads that MRgFUS can support, creating new intersections with pharmaceutical development and oncology research programs.

Operationally, there is a pronounced shift toward decentralized care models and ambulatory procedural settings for appropriate indications. This transition is tempered by the need for robust training programs, service-level agreements, and cross-disciplinary governance to ensure patient safety and reproducible outcomes. Taken together, these shifts indicate a maturing ecosystem where clinical utility, interoperability, and strategic partnerships determine long-term value rather than simple technology possession.

Assessing the supply chain, procurement, and commercial model adjustments prompted by cumulative United States tariff measures affecting MR-guided focused ultrasound in 2025

The cumulative impact of tariff actions in 2025 presents a complex set of operational and strategic considerations for stakeholders in the MRgFUS value chain. Tariffs on imported components, imaging subsystems, and precision manufacturing inputs increase the cost basis for systems manufacturers and can reverberate through distribution channels. These cost pressures frequently prompt manufacturers to reassess supplier footprints, accelerate localization of critical components, and renegotiate supply agreements to preserve gross margins and avoid abrupt price shifts for institutional buyers.

Beyond direct cost implications, tariffs create timing and logistics challenges. Procurement cycles for capital equipment tend to be long, and uncertainty around duties can delay purchases or prompt institutions to favor already-localized vendors. For manufacturers that rely on specialized overseas expertise for assembly or calibration, tariffs can incentivize nearshoring or the establishment of regional service hubs to maintain competitiveness. These adaptive strategies require upfront investment but can yield more resilient supply chains over time.

Regulatory and contracting processes are also affected. Hospitals and ambulatory centers operating under fixed capital budgets may defer acquisitions during periods of tariff volatility, impacting revenue cycles for providers that offer MRgFUS as a service. In response, vendors are increasingly offering flexible commercial models, including consumable revenue streams, managed service agreements, and phased financing structures to mitigate buyer uncertainty. Ultimately, the tariff environment in 2025 acts as an accelerant for supply chain redesign, regional manufacturing strategies, and commercial model innovation, compelling stakeholders to prioritize agility and diversified sourcing.

Deep segmentation insights revealing how end-user specialties, therapeutic mechanisms, product offerings, and clinical indications shape adoption, evidence needs, and commercialization tactics

A robust segmentation framework reveals nuanced implications for clinical adoption, product development, and commercialization across end users, mechanisms, offerings, and indications. When viewing the market through end-user lenses, ambulatory surgical centers emerge with sub-specializations such as cancer centers and imaging centers that prioritize throughput, patient experience, and predictable procedure times, while hospitals, both private and public, focus on integration with complex care pathways and institutional credentialing. Research institutes split between academic research institutions and pharmaceutical R&D labs, emphasizing translational studies and partnerships for drug delivery, and specialty clinics like neurosurgery and oncology centers concentrate on high-acuity cases and multidisciplinary coordination.

Mechanism-based segmentation clarifies development trajectories and clinical partnerships. Platforms enabling blood-brain barrier opening with reversible disruption attract collaborations with neurologists and pharmaceutical developers pursuing targeted CNS delivery. Drug delivery mechanisms, including encapsulated carriers, microbubble-mediated techniques, and targeted delivery platforms, link closely with translational research and clinical trial design. Histotripsy, characterized by cavitation-induced tissue fractionation, and neuromodulation approaches spanning deep brain stimulation analogs and noninvasive techniques, each require distinct regulatory strategies and clinician training. Thermal ablation, delivered through focused ultrasound ablation methods, aligns with surgical and oncologic workflows and tends to be the most familiar entry point for surgical teams.

Offering segmentation differentiates commercial models and lifecycle support requirements. Accessories and parts, encompassing accessories, consumables, and replacement parts, create recurring revenue opportunities and necessitate robust logistics. Services such as consulting and training as well as installation and maintenance are critical to adoption, particularly for institutions implementing complex imaging-guided procedures. Systems themselves bifurcate between MR-guided systems and ultrasound-guided systems; MR-guided platforms further diverge into fully integrated and retrofit systems, while ultrasound-guided offerings distinguish between integrated coils and standalone systems. Each subcategory carries implications for capital planning, staff competencies, and service ecosystems.

Indication-driven segmentation highlights clinical prioritization and evidence generation pathways. Applications range from bone metastases, breast cancer, essential tremor, liver tumors, pancreatic tumors, prostate cancer, and uterine fibroids to a spectrum of neurological disorders. Within neurological disorders, subcategories such as brain tumors, movement disorders, neuropathic pain, and Parkinson's disease require bespoke trial designs, multidisciplinary care pathways, and long-term outcome tracking. Mapping these segments against payer landscapes and institutional capabilities enables targeted commercialization and clinical research strategies that align with patient need and reimbursement viability.

How regional regulatory diversity, infrastructure priorities, and clinical collaboration models across the Americas, EMEA, and Asia-Pacific influence adoption and commercialization strategies

Regional dynamics play a decisive role in shaping clinical adoption, regulatory strategy, and commercial execution. In the Americas, institutional investment appetite is tempered by reimbursement frameworks, clinical guideline evolution, and the maturity of interventional radiology and neurosurgical centers. Patient demand in tertiary referral centers and integrated cancer programs is converging with interest from ambulatory surgical models that can offer lower-cost, high-throughput care for select indications. These forces shape vendor go-to-market priorities and the structuring of service agreements to align with hospital procurement cycles.

Europe, the Middle East, and Africa present a heterogeneous landscape where regulatory alignment across distinct national health systems and centralized procurement in some countries coexist with highly specialized private providers in others. Clinical adoption is often influenced by national guideline endorsements and demonstration projects within academic centers that then catalyze broader uptake. Service and training partnerships are particularly important in this region, as centers seek capacity-building support to translate clinical evidence into routine practice.

Asia-Pacific is characterized by rapid infrastructure investment, an expanding base of advanced imaging centers, and strong government-led initiatives to bolster domestic manufacturing capabilities. Several markets within the region are prioritizing localized production and skills development, which creates potential opportunities for manufacturers prepared to invest in localized support. Across all regions, cross-border collaborations in clinical research and shared registries are emerging as critical mechanisms for accelerating evidence generation and harmonizing best practices.

Competitive ecosystem analysis emphasizing how manufacturers, innovative entrants, and strategic partnerships drive technology differentiation, service models, and clinical collaboration

Key company dynamics are defined less by singular market leaders and more by an ecosystem of device manufacturers, imaging partners, clinical research organizations, and specialized service providers. Established medical device manufacturers bring strengths in regulatory experience, global service networks, and capital access, which enable them to scale complex installations and offer integrated maintenance contracts. At the same time, innovative startups are driving differentiation through focused clinical programs, algorithmic treatment planning, and novel mechanisms such as enhanced blood-brain barrier modulation and microbubble-assisted delivery.

Strategic partnerships are increasingly central to competitive positioning. Collaborations between device vendors and pharmaceutical developers create co-development pathways for indications that marry focused ultrasound delivery with targeted therapeutics. Similarly, alliances with imaging vendors and systems integrators facilitate smoother workflow integration and reduce adoption friction at hospital sites. Service providers that specialize in training and clinical workflow optimization add value by shortening the learning curve for new adopters and improving first-case success rates.

Given the capital intensity of system deployment, companies that offer flexible commercial arrangements-leasing, managed services, or outcome-linked models-can accelerate adoption among budget-constrained institutions. The competitive landscape also rewards firms that invest in robust real-world evidence programs and registries, as longitudinal clinical outcomes will increasingly inform payer decisions and guideline formulation.

Actionable strategic playbook for industry leaders to accelerate adoption, anchor clinical partnerships, and de-risk commercial and supply chain execution in MRgFUS

Industry leaders should adopt a multi-pronged strategy that aligns technology development, clinical evidence generation, and commercial flexibility to accelerate adoption and de-risk investment. First, prioritize modular product architectures and retrofit options that reduce upfront capital barriers for health systems, enabling faster proof-of-concept deployments in academic and high-volume community centers. This approach should be complemented by targeted training and certification programs that reduce variability in clinical outcomes and build institutional champions.

Second, invest in strategic alliances with pharmaceutical developers and translational research centers to co-design trials that demonstrate the unique value proposition of combining focused ultrasound with targeted therapeutic agents. These collaborations can open new reimbursement pathways and create differentiated clinical indications that are difficult for competitors to replicate. Simultaneously, vendors should develop comprehensive service models that include installation, ongoing maintenance, and clinical workflow consultancy to minimize operational friction and maximize uptime.

Third, diversify supply chains and consider regional manufacturing or assembly hubs to mitigate tariff exposure and logistics risk. Building local service capabilities reduces time-to-repair and strengthens relationships with institutional purchasers. Finally, adopt data-driven commercialization strategies: deploy registries, real-world evidence collection, and outcome analytics to demonstrate long-term value and support payer negotiations. By executing these recommendations, industry leaders can create a defensible market position that balances innovation with scalability.

Transparent description of a mixed-methods research approach combining primary clinical interviews, secondary evidence synthesis, and expert validation to ensure robust actionable insights

The research methodology underpinning this executive summary integrates primary qualitative engagement, rigorous secondary analysis, and iterative expert validation to ensure credibility and practical relevance. Primary inputs were gathered through structured interviews with clinical leaders across neurosurgery, interventional radiology, and oncology, as well as procurement and technical operations stakeholders who manage imaging suites and capital planning processes. These conversations provided firsthand insights into clinical workflows, training needs, and procurement decision criteria.

Secondary research reviewed peer-reviewed clinical literature, regulatory filings, device technical specifications, and publicly available clinical guidelines to triangulate clinical efficacy, safety considerations, and regulatory pathways. Market intelligence was synthesized by mapping technology roadmaps, patent activity, and partnerships to identify strategic trends and innovation vectors. Data triangulation and cross-validation steps reconciled divergent perspectives and ensured that conclusions reflected both clinical realities and commercial imperatives.

Finally, findings were subjected to expert panel review, where thought leaders from clinical, regulatory, and commercial domains critiqued assumptions, validated segmentation frameworks, and recommended interpretative adjustments. Quality controls included source provenance tracking, conflict-of-interest assessments for interviewees, and iterative revisions to ensure clarity and actionable relevance for decision-makers seeking to deploy or invest in MRgFUS capabilities.

Synthesis and forward-looking assessment highlighting the coordinated actions required from manufacturers, clinicians, and payers to realize sustained MRgFUS adoption

In conclusion, MR-guided focused ultrasound stands at an inflection point where clinical innovation, commercialization strategy, and operational execution intersect to determine the pace and scale of adoption. Clinical evidence expansion, modular technology trends, and strategic collaborations with pharmaceutical and imaging partners are collectively redefining what is possible for noninvasive therapies and targeted drug delivery. Institutional adoption will hinge on the ability of stakeholders to integrate technology into clinical pathways while ensuring consistent training, service reliability, and outcome measurement.

External forces such as tariff environments, regional regulatory diversity, and capital procurement practices will shape vendor strategies around localization, flexible commercial terms, and service offerings. Companies that proactively address supply chain resilience, invest in real-world evidence, and design scalable training programs will be best positioned to convert clinical promise into routine care. For health systems and research institutions, the imperative is to align clinical priorities with measurable outcome goals and to leverage strategic partnerships that accelerate translational research and patient access.

Overall, the pathway to broad adoption depends on coordinated efforts across manufacturers, clinical champions, service providers, and payers to demonstrate sustained clinical benefit, operational viability, and economic value. Stakeholders who act decisively to address these dimensions will shape the next generation of therapeutic care enabled by MRgFUS.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Mechanism

  • 8.1. Blood Brain Barrier Opening
  • 8.2. Drug Delivery
    • 8.2.1. Encapsulated Drug Carriers
    • 8.2.2. Microbubble Mediated Delivery
    • 8.2.3. Targeted Delivery
  • 8.3. Histotripsy
  • 8.4. Neuromodulation
    • 8.4.1. Deep Brain Stimulation
    • 8.4.2. Non Invasive Neuromodulation
  • 8.5. Thermal Ablation

9. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Offering

  • 9.1. Accessories And Parts
    • 9.1.1. Accessories
    • 9.1.2. Consumables
    • 9.1.3. Replacement Parts
  • 9.2. Services
    • 9.2.1. Consulting And Training
    • 9.2.2. Installation And Maintenance
  • 9.3. Systems
    • 9.3.1. MR Guided Systems
    • 9.3.2. Ultrasound Guided Systems

10. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by End User

  • 10.1. Ambulatory Surgical Centers
    • 10.1.1. Cancer Centers
    • 10.1.2. Imaging Centers
  • 10.2. Hospitals
    • 10.2.1. Private Hospitals
    • 10.2.2. Public Hospitals
  • 10.3. Research Institutes
    • 10.3.1. Academic Research Institutes
    • 10.3.2. Pharmaceutical R&D Labs
  • 10.4. Specialty Clinics
    • 10.4.1. Neurosurgery Centers
    • 10.4.2. Oncology Centers

11. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Indication

  • 11.1. Bone Metastases
  • 11.2. Breast Cancer
  • 11.3. Essential Tremor
  • 11.4. Liver Tumors
  • 11.5. Neurological Disorders
    • 11.5.1. Brain Tumors
    • 11.5.2. Movement Disorders
    • 11.5.3. Neuropathic Pain
    • 11.5.4. Parkinsons Disease
  • 11.6. Pancreatic Tumors
  • 11.7. Prostate Cancer
  • 11.8. Uterine Fibroids

12. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Magnetic Resonance Guided Focused Ultrasound Therapy System Market

16. China Magnetic Resonance Guided Focused Ultrasound Therapy System Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alpinion Medical Systems Co., Ltd.
  • 17.6. Canon Medical Systems Corporation
  • 17.7. Chongqing Haifu Technology Co., Ltd.
  • 17.8. EDAP TMS SA
  • 17.9. EDAP-affiliated product lines
  • 17.10. EpiSonica
  • 17.11. EyeTechCare
  • 17.12. FUJIFILM Holdings
  • 17.13. FUS Instruments
  • 17.14. General Electric Company
  • 17.15. Hitachi, Ltd.
  • 17.16. Insightec Ltd.
  • 17.17. Koninklijke Philips N.V.
  • 17.18. Medtronic plc
  • 17.19. Mianyang Sonic Electronic
  • 17.20. Mirabilis Medical
  • 17.21. Profound Medical
  • 17.22. Shanghai A&S Science & Technology
  • 17.23. Shenzhen Wikkon Medical Technology
  • 17.24. Siemens Healthineers AG
  • 17.25. SonaCare Medical
  • 17.26. SuperSonic Imagine
  • 17.27. Theraclion SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BLOOD BRAIN BARRIER OPENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BLOOD BRAIN BARRIER OPENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BLOOD BRAIN BARRIER OPENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ENCAPSULATED DRUG CARRIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ENCAPSULATED DRUG CARRIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ENCAPSULATED DRUG CARRIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MICROBUBBLE MEDIATED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MICROBUBBLE MEDIATED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MICROBUBBLE MEDIATED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY TARGETED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY TARGETED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HISTOTRIPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HISTOTRIPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HISTOTRIPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DEEP BRAIN STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DEEP BRAIN STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NON INVASIVE NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NON INVASIVE NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NON INVASIVE NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY THERMAL ABLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY THERMAL ABLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY THERMAL ABLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY REPLACEMENT PARTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY REPLACEMENT PARTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY REPLACEMENT PARTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CONSULTING AND TRAINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CONSULTING AND TRAINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CONSULTING AND TRAINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INSTALLATION AND MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INSTALLATION AND MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INSTALLATION AND MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MR GUIDED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MR GUIDED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MR GUIDED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND GUIDED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND GUIDED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND GUIDED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PHARMACEUTICAL R&D LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PHARMACEUTICAL R&D LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PHARMACEUTICAL R&D LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROSURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROSURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROSURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BONE METASTASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BONE METASTASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BONE METASTASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ESSENTIAL TREMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ESSENTIAL TREMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY LIVER TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY LIVER TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY LIVER TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BRAIN TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BRAIN TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BRAIN TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MOVEMENT DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MOVEMENT DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MOVEMENT DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PARKINSONS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PARKINSONS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PANCREATIC TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PANCREATIC TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PANCREATIC TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY UTERINE FIBROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY UTERINE FIBROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY UTERINE FIBROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)